NASDAQ:TCRX TScan Therapeutics Q2 2025 Earnings Report $2.31 +0.02 (+0.87%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.32 +0.01 (+0.43%) As of 10/24/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast TScan Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS -$0.28Beat/MissMissed by -$0.00One Year Ago EPSN/ATScan Therapeutics Revenue ResultsActual Revenue$3.08 millionExpected Revenue$1.31 millionBeat/MissBeat by +$1.77 millionYoY Revenue GrowthN/ATScan Therapeutics Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time7:00AM ETUpcoming EarningsTScan Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TScan Therapeutics Earnings HeadlinesTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 17, 2025 | americanbankingnews.com2 Overlooked Stocks to Snap Up in 2025October 16, 2025 | msn.comMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff, as the world's biggest car firm prepares to launch a "mind blowing" new product. It has nothing to do with EVs, or self-driving cars. In fact, it's not a car at all... | Altimetry (Ad)TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025September 17, 2025 | globenewswire.comTScan Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2025 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash WiselyAugust 15, 2025 | finance.yahoo.comSee More TScan Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email. Email Address About TScan TherapeuticsTScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins. The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors. TScan has established strategic collaborations with major pharmaceutical partners to advance its lead candidates through clinical development. These partnerships enable the company to combine its TCR discovery capabilities with the resources and expertise of established drug developers, while retaining the ability to progress additional assets independently. Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan Therapeutics went public in late 2021. Under the leadership of Chief Executive Officer Kenneth Song, the company employs a multidisciplinary team of immunologists, molecular biologists and data scientists. While its core operations are based in the United States, TScan’s research partnerships and clinical trial activities extend globally, reflecting its ambition to deliver novel T-cell therapies to patients around the world.View TScan Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
